Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Vaxcyte (PCVX) Asset Writedowns and Impairment (2022)

Vaxcyte (PCVX) has 1 years of Asset Writedowns and Impairment data on record, last reported at -$13000.0 in Q4 2022.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to -$13000.0 in Q4 2022 year-over-year; TTM through Sep 2023 was -$13000.0, a 106.1% decrease, with the full-year FY2022 number at $200000.0, changed N/A from a year prior.
Asset Writedowns and Impairment reached -$13000.0 in Q4 2022 per PCVX's latest filing, down from $156000.0 in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for PCVX hit a ceiling of $156000.0 in Q2 2022 and a floor of -$13000.0 in Q4 2022.